United States Breast Cancer Therapeutics Market is Expected to be Dominated by Chemotherapy through 2028
The growing prevalence of breast cancer is expected to
drive the growth of the United States breast cancer therapeutics market during the forecast
period.
According to TechSci
Research report, “United States Breast
Cancer Therapeutics - By Region, Competition,
Forecast, and Opportunities, 2018-2028”, the United States breast cancer therapeutics market is
anticipated to expand at a remarkable rate during the projected period, owing
to several drivers such as rising incidence of breast cancer, improvements in
cancer biology and pharmacology that support treatment development, rising
R&D investment, the introduction of several diagnostic and screening
programs, and favorable insurance and reimbursement policies.
In the US, breast
cancer affects one in eight women at some point in their lifetime, making it
the most prevalent type of cancer among women. The country has a sizable market
for breast cancer therapeutics as a result, and it is expected that this
market will expand over the coming years. The industry offers a variety of
medical interventions, such as targeted therapies, hormone therapy, surgery,
chemotherapy, and radiation therapy. The breast cancer therapeutics market in
the United States is poised for further growth and innovation in the years to
come due to ongoing research and development in the field of breast cancer
therapy and a rising number of breast cancer patients.
The COVID-19 pandemic
has significantly affected the breast cancer therapeutics market in the
United States due to disruptions in the healthcare system, delay in cancer
screenings and diagnosis, and shortages of some cancer medicines and
medical supplies. Financial difficulties have been brought on by the pandemic
for both patients and the healthcare sector. The implementation of digital technologies
in healthcare has grown, resulting in higher efficiencies and better patient
outcomes, and the industry has demonstrated its adaptability by putting new
standards and safety measures in effect.
Browse over 30 market
data Figures spread through 70 Pages and an in-depth TOC on "United States breast cancer therapeutics market"
The United
States breast cancer therapeutics market can be segmented by therapy, end user, and region.
Based on therapy,
the market can be segmented into chemotherapy, hormone therapy, immunotherapy,
targeted therapy, and others. Due to its success in treating a variety of
breast cancer cases, chemotherapy is predicted to dominate the US market for
breast cancer therapeutics in the coming years. Chemotherapy is still the most
popular form of treatment for breast cancer, despite the availability of
alternatives such as radiation therapy, targeted therapy, and hormonal therapy.
Chemotherapy medications have generated more interest in the market due to
their promising performance in reducing tumor size and halting the spread of
cancer cells. Additionally, this market segment is anticipated to grow in the
near future due to ongoing improvements in chemotherapy drugs and personalized
treatment methods.
In terms of end
user, the market can be divided into hospitals, specialty clinics, ambulatory
surgical centers, and others. Due to the increased demand for
cutting-edge treatment options and the increasing prevalence of breast cancer,
the hospital segment is anticipated to dominate the United States breast cancer
therapeutics market n the next years. Hospitals provide a wide range of
services such as diagnostic exams, surgeries, radiation therapy, and
chemotherapy that are crucial in the treatment of breast cancer. Additionally,
hospitals have state-of-the-art infrastructure and a staff of highly qualified
medical specialists, allowing them to offer comprehensive care to patients with
breast cancer. The hospital sector is anticipated to have significant
development in the coming years due to the growing emphasis on the early
detection and treatment of breast cancer.
Based on the region,
the market can be classified into following categories, Northeast Region,
Midwest Region, South Region, and West Region. Due to several factors, the
Northeastern United States is likely to dominate the breast cancer treatments
market in the coming years. The region has a greater incidence of breast cancer
than other areas of the nation, which increases the need for treatment. The
Northeast is also home to several prominent cancer centers and research organizations,
which draw top talent and funding and help progress breast cancer treatments.
Furthermore, the area has a higher concentration of medical facilities and
insurance coverage, making patients' access to and cost of breast cancer treatment
easier to manage. The Northeast is well-positioned to dominate the breast
cancer treatments industry in the coming years due to an amalgamation of these
features.
Major companies
operating in United States breast cancer therapeutics market include:
- AstraZeneca PLC
- Eli Lilly and Company
- Genentech
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Seattle Genetics, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“Technology innovations,
rising breast cancer prevalence, and increasing patient awareness have
contributed to the tremendous rise of the United States breast cancer therapeutics
market in recent years. However, the market also must deal with a number of
challenges, such as exorbitant treatment costs, therapy side effects, and legal
restrictions. However, the market is observing several trends, including the
development of targeted therapies, the use of precision medicine, and the
uptake of immunotherapy. Clinical studies and research are also being done to
create novel cures and treatments for breast cancer, and businesses are
spending money to patent their goods to obtain a competitive edge,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based global
management consulting firm.
“United
States Breast Cancer Therapeutics Market, By Therapy {Chemotherapy
(Anthracyclines, Taxanes, Antimetabolites, and Others), Hormone Therapy
(Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Others),
Immunotherapy, Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase
Inhibitor, Herceptin, and Others), and Others}, By End User (Hospitals,
Specialty Clinics, Ambulatory Surgical Centers, and Others), By Region,
Competition, Forecast & Opportunities, 2028”, has evaluated the future growth
potential of the United States breast cancer therapeutics market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the United States breast cancer therapeutics
market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com